IMCR
Immunocore Holdings plc
Key Financials
Net Income
$-35514000
↑ 30.5%
Operating Income
$-45353000
↑ 35.6%
Total Assets
$1.1B
↑ 5.7%
EPS (Diluted)
$-0.71
↑ 30.4%
Revenue
$400.0M
↑ 29.0%
Total Liabilities
$686.2M
↑ 5.8%
Shareholders' Equity
$381.0M
↑ 5.6%
Operating Cash Flow
$-10712000.00
↓ 141.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| S-8 | 5/8/2026 | View on SEC |
| 8-K | 5/6/2026 | View on SEC |
| 10-Q | 5/6/2026 | View on SEC |
| ARS | 4/16/2026 | View on SEC |
| DEF 14A | 4/16/2026 | View on SEC |
| 144 | 4/8/2026 | View on SEC |
| 144 | 3/11/2026 | View on SEC |
| SCHEDULE 13G/A | 3/6/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IMCR |
| Company Name | Immunocore Holdings plc |
| CIK | 1671927 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | X0 |
| Phone | 01235 5430281 |